PROTHENA CORP PUBLIC LTD CO(PRTA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 4 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PRTA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for PROTHENA CORP PUBLIC LTD CO (PRTA), a Healthcare sector company. PRTA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 4 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), PROTHENA CORP PUBLIC LTD CO reports quarterly revenue of $51.1M, net income of $32.7M, free cash flow of $28.9M. Top institutional holders of PRTA by reported 13-F value include Prosight Management,, NewEdge Advisors,, LAZARD ASSET MANAGEMENT, based on the most recent SEC filings. PRTA trades on the Nasdaq exchange and files with the SEC under CIK 1559053. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PROTHENA CORP PUBLIC LTD CO directly from SEC EDGAR.
Revenue
Q1 2026
$51.1M
Net Income
Q1 2026
$32.7M
Free Cash Flow
Q1 2026
$28.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-92.8% YoYNet Income
-99.6% YoYOperating Income
-38.9% YoYEPS (Diluted)
-99.6% YoYTotal Assets
-40.3% YoYOp. Cash Flow
-9.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $9.7M -92.8% | $135.2M +47.9% | $91.4M +69.5% | $53.9M +6219.5% | $853.0K +4.8% | $814.0K |
| Net Income | $-244.1M -99.6% | $-122.3M +16.8% | $-147.0M -25.7% | $-116.9M -5.2% | $-111.1M -43.1% | $-77.7M |
| Operating Income | $-214.6M -38.9% | $-154.6M +19.1% | $-191.0M -45.2% | $-131.6M -16.7% | $-112.7M -31.5% | $-85.7M |
| EPS (Diluted) | $-4.53 -99.6% | $-2.27 +17.8% | $-2.76 -11.7% | $-2.47 +11.2% | $-2.78 -42.6% | $-1.95 |
| Total Assets | $326.8M -40.3% | $547.1M -21.4% | $696.4M -8.1% | $758.0M +127.7% | $333.0M -20.6% | $419.3M |
| Operating Cash Flow | $-163.6M -9.0% | $-150.1M -12.1% | $-133.9M -23.1% | $-108.8M -35.4% | $-80.4M -51.7% | $-53.0M |
AI Insight: PRTA Financial Trends
PRTA swung to $51M revenue and $33M profit in Q1 2026 after seven consecutive quarters of losses.
• Revenue jumped from $0M in Q4 2025 to $51M in Q1 2026, breaking a streak of minimal quarterly revenues.
• Net income turned positive at $33M in Q1 2026 after seven straight quarters of losses averaging $55M per quarter.
• Operating cash flow improved from negative $23M in Q4 2025 to positive $29M in Q1 2026.
• Equity declined from $582M in Q2 2024 to $280M in Q4 2025 before recovering to $313M in Q1 2026.
⚠ Revenue sustainability after Q1 2026 spike, given the company's history of lumpy quarterly revenues in biotech partnerships.
⚠ Equity base eroded $269M over six quarters through Q4 2025 before latest quarter recovery.
AI Insight: PRTA Ratio Trends
Prothena swung from deeply negative returns to strong profitability in Q1 2026, with ROIC recovering from -59.9% in Q1 2025 to 38.4%.
• Operating margin jumped to 58.8% in Q1 2026 after being absent for seven consecutive quarters.
• ROIC recovered dramatically from -59.9% in Q1 2025 to 38.4% in Q1 2026.
• ROE improved from -30.8% in Q4 2025 to 41.9% in Q1 2026.
⚠ Volatile earnings pattern with extreme swings between profitable and loss quarters over past two years.
⚠ TTM metrics remain deeply negative despite strong Q1 2026 performance, indicating recent turnaround.
Get alerted when PRTA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for PROTHENA CORP PUBLIC LTD CO including:
Top Institutional Holders of PRTA
Prosight Management, LP
$127.2K3,500 shNewEdge Advisors, LLC
$2.6K72 shLAZARD ASSET MANAGEMENT LLC
$154.004,256 shDaiwa Securities Group Inc.
$7.00195 sh
| Fund | Value | Shares |
|---|---|---|
| Prosight Management, LP | $127.2K | 3,500 |
| NewEdge Advisors, LLC | $2.6K | 72 |
| LAZARD ASSET MANAGEMENT LLC | $154.00 | 4,256 |
| Daiwa Securities Group Inc. | $7.00 | 195 |
More Healthcare Companies
View all Healthcare →Put PRTA on your watchlist
Track score changes the day PROTHENA CORP PUBLIC LTD CO files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PRTA a good stock to buy?
13F Pro's AI-powered analysis of PROTHENA CORP PUBLIC LTD CO (PRTA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRTA are available on the PRTA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own PRTA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRTA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PROTHENA CORP PUBLIC LTD CO's investment landscape.